JP2005519917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519917A5 JP2005519917A5 JP2003563495A JP2003563495A JP2005519917A5 JP 2005519917 A5 JP2005519917 A5 JP 2005519917A5 JP 2003563495 A JP2003563495 A JP 2003563495A JP 2003563495 A JP2003563495 A JP 2003563495A JP 2005519917 A5 JP2005519917 A5 JP 2005519917A5
- Authority
- JP
- Japan
- Prior art keywords
- cartilage
- delivery system
- targeted
- drug delivery
- targeted drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000845 cartilage Anatomy 0.000 claims 99
- 238000012377 drug delivery Methods 0.000 claims 53
- 230000015556 catabolic process Effects 0.000 claims 33
- 239000003112 inhibitor Substances 0.000 claims 22
- 230000001195 anabolic effect Effects 0.000 claims 18
- 239000003223 protective agent Substances 0.000 claims 11
- 230000000890 antigenic effect Effects 0.000 claims 10
- 239000003042 chondroprotective agent Substances 0.000 claims 10
- 230000015572 biosynthetic process Effects 0.000 claims 9
- 210000001188 articular cartilage Anatomy 0.000 claims 8
- 239000002105 nanoparticle Substances 0.000 claims 6
- 230000001012 protector Effects 0.000 claims 5
- 108010067219 Aggrecans Proteins 0.000 claims 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 4
- 102000000503 Collagen Type II Human genes 0.000 claims 4
- 108010041390 Collagen Type II Proteins 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000002633 protecting effect Effects 0.000 claims 4
- 229940044551 receptor antagonist Drugs 0.000 claims 4
- 239000002464 receptor antagonist Substances 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 102100036601 Aggrecan core protein Human genes 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 3
- 108010035532 Collagen Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 229920001436 collagen Polymers 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 210000003035 hyaline cartilage Anatomy 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 102000016611 Proteoglycans Human genes 0.000 claims 2
- 108010067787 Proteoglycans Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 229940125388 beta agonist Drugs 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 239000004633 polyglycolic acid Substances 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 210000002437 synoviocyte Anatomy 0.000 claims 2
- CVYPRDPBCXSVBN-WDZFZDKYSA-N (5z)-5-[[5-[(4-chlorophenyl)methylsulfanyl]-1-methyl-3-(trifluoromethyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=C(Cl)C=CC=1CSC=1N(C)N=C(C(F)(F)F)C=1\C=C1/SC(=S)NC1=O CVYPRDPBCXSVBN-WDZFZDKYSA-N 0.000 claims 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 102100027401 A disintegrin and metalloproteinase with thrombospondin motifs 3 Human genes 0.000 claims 1
- 102100032638 A disintegrin and metalloproteinase with thrombospondin motifs 5 Human genes 0.000 claims 1
- 108091005664 ADAMTS4 Proteins 0.000 claims 1
- 108091005663 ADAMTS5 Proteins 0.000 claims 1
- 102000016284 Aggrecans Human genes 0.000 claims 1
- 229940122902 Arachidonic acid inhibitor Drugs 0.000 claims 1
- 102000004954 Biglycan Human genes 0.000 claims 1
- 108090001138 Biglycan Proteins 0.000 claims 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 claims 1
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 claims 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 claims 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 claims 1
- 102100027995 Collagenase 3 Human genes 0.000 claims 1
- 108050005238 Collagenase 3 Proteins 0.000 claims 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 1
- 102000004237 Decorin Human genes 0.000 claims 1
- 108090000738 Decorin Proteins 0.000 claims 1
- 101800001224 Disintegrin Proteins 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 1
- 101000730032 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 5 Proteins 0.000 claims 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 claims 1
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 229940118432 Interleukin receptor antagonist Drugs 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 229940122920 Kallikrein inhibitor Drugs 0.000 claims 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102100030411 Neutrophil collagenase Human genes 0.000 claims 1
- 101710118230 Neutrophil collagenase Proteins 0.000 claims 1
- 102000003840 Opioid Receptors Human genes 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 claims 1
- 229940127315 Potassium Channel Openers Drugs 0.000 claims 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 claims 1
- 102000014400 SH2 domains Human genes 0.000 claims 1
- 108050003452 SH2 domains Proteins 0.000 claims 1
- 102100025421 Serine protease inhibitor Kazal-type 6 Human genes 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- 101710108790 Stromelysin-1 Proteins 0.000 claims 1
- 108060008245 Thrombospondin Proteins 0.000 claims 1
- 102000002938 Thrombospondin Human genes 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 239000003152 bradykinin antagonist Substances 0.000 claims 1
- 229940045110 chitosan Drugs 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229940014259 gelatin Drugs 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229940099552 hyaluronan Drugs 0.000 claims 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000017953 prostanoid receptors Human genes 0.000 claims 1
- 108050007059 prostanoid receptors Proteins 0.000 claims 1
- 239000003881 protein kinase C inhibitor Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000003227 purinergic agonist Substances 0.000 claims 1
- 239000000111 purinergic antagonist Substances 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000002344 surface layer Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 210000001258 synovial membrane Anatomy 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000002462 tachykinin receptor antagonist Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35355202P | 2002-02-01 | 2002-02-01 | |
| PCT/US2003/003175 WO2003063799A2 (en) | 2002-02-01 | 2003-01-31 | Compositions and methods for systemic inhibition of cartilage degradation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519917A JP2005519917A (ja) | 2005-07-07 |
| JP2005519917A5 true JP2005519917A5 (es) | 2005-12-22 |
Family
ID=27663221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003563495A Withdrawn JP2005519917A (ja) | 2002-02-01 | 2003-01-31 | 軟骨分解の全身阻害のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1496835A4 (es) |
| JP (1) | JP2005519917A (es) |
| KR (1) | KR20040094413A (es) |
| CN (1) | CN1697647A (es) |
| AU (1) | AU2003212898B2 (es) |
| CA (1) | CA2474645C (es) |
| MX (1) | MXPA04007124A (es) |
| WO (1) | WO2003063799A2 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| EP1594459B1 (en) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| DE10304994A1 (de) * | 2003-02-07 | 2004-09-02 | Aventis Pharma Deutschland Gmbh | Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose |
| CN1798769A (zh) | 2003-05-12 | 2006-07-05 | 内蒂穆恩公司 | 抗masp－2抗体 |
| JP2007517913A (ja) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ， インコーポレイテッド | カルシトニン遺伝子関連ペプチドを投与することによって急性心筋梗塞を処置するための方法およびカルシトニン遺伝子関連ペプチドを含有する組成物 |
| JP2007517912A (ja) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ， インコーポレイテッド | 心脈管および腎臓の適応症のための制御放出ｃｇｒｐ送達組成物 |
| ATE515268T1 (de) * | 2004-05-25 | 2011-07-15 | Stryker Corp | Verwendung von op-1 zur behandlung von knorpeldefekten |
| AU2011265308B2 (en) * | 2004-05-25 | 2014-06-26 | Stryker Corporation | Use of Morphogenic Proteins for Treating Cartilage Defects |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| PT1753456T (pt) | 2004-06-10 | 2016-11-04 | Univ Leicester | Métodos para tratar condições associadas com a ativação do complemento dependente de masp-2 |
| CN101141948B (zh) * | 2005-03-14 | 2011-08-24 | 佰威控股有限公司 | 药物递送组合物及相关方法 |
| SI1940465T1 (sl) | 2005-10-26 | 2012-10-30 | Novartis Ag | Nova uporaba protiteles proti IL-1 beta |
| ES2542511T3 (es) | 2007-05-11 | 2015-08-06 | Adynxx, Inc. | Expresión génica y dolor |
| EP2259774B1 (en) | 2008-02-27 | 2012-12-12 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
| US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
| CN106390117A (zh) | 2009-10-16 | 2017-02-15 | 奥默罗斯公司 | 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法 |
| MX355648B (es) | 2011-04-08 | 2018-04-26 | Univ Leicester | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| PT2704743T (pt) | 2011-05-04 | 2020-06-17 | Omeros Corp | Composições para inibir a ativação de complemento dependente de masp-2 |
| CA2872901A1 (en) | 2012-05-10 | 2013-11-14 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| BR112015024758A2 (pt) * | 2013-03-29 | 2017-10-24 | Merrimack Pharmaceuticals Inc | proteínas de fusão de ligação à cartilagem |
| IL283373B1 (en) | 2013-10-17 | 2024-04-01 | Omeros Corp | Pharmaceutical preparations containing MASP-2 suppressors to suppress MASP-2-dependent complement activation and related diseases |
| US9833474B2 (en) | 2013-11-26 | 2017-12-05 | Biomet Biologies, LLC | Methods of mediating macrophage phenotypes |
| EP3626822A1 (en) | 2014-08-15 | 2020-03-25 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
| US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
| JP6508670B2 (ja) * | 2014-12-26 | 2019-05-08 | 国立大学法人広島大学 | 軟骨変性抑制剤 |
| US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
| CN117398458A (zh) | 2015-11-09 | 2024-01-16 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
| CN106390099A (zh) * | 2016-11-07 | 2017-02-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种牙髓干细胞组合物及其应用 |
| TW202402809A (zh) | 2017-08-15 | 2024-01-16 | 美商歐米諾斯公司 | 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法 |
| CN112274646B (zh) * | 2019-07-12 | 2023-06-02 | 北京茵诺医药科技有限公司 | 用于靶向活化cd44分子的双亲性蛋白质-高分子结合体递送系统、其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04502854A (ja) * | 1988-10-24 | 1992-05-28 | カターソン，ブルース | 変形性関節症の初期段階の診断、モニタリングならびに治療の方法および組成物 |
| US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
| WO2001007067A2 (en) * | 1999-07-21 | 2001-02-01 | Omeros Medical Systems, Inc. | Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| DE69937070D1 (de) * | 1998-11-05 | 2007-10-18 | Omeros Corp | Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung |
| EP1401818A2 (en) * | 2001-05-30 | 2004-03-31 | Targesome, Inc. | Targeted multivalent macromolecules |
| US6998019B2 (en) * | 2002-09-10 | 2006-02-14 | Fibermark, Inc. | Glazed paper webs |
-
2003
- 2003-01-31 CA CA2474645A patent/CA2474645C/en not_active Expired - Fee Related
- 2003-01-31 JP JP2003563495A patent/JP2005519917A/ja not_active Withdrawn
- 2003-01-31 WO PCT/US2003/003175 patent/WO2003063799A2/en active Search and Examination
- 2003-01-31 KR KR10-2004-7011603A patent/KR20040094413A/ko not_active Application Discontinuation
- 2003-01-31 MX MXPA04007124A patent/MXPA04007124A/es active IP Right Grant
- 2003-01-31 CN CNA038031361A patent/CN1697647A/zh active Pending
- 2003-01-31 AU AU2003212898A patent/AU2003212898B2/en not_active Ceased
- 2003-01-31 EP EP03708941A patent/EP1496835A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519917A5 (es) | ||
| CA2474645A1 (en) | Compositions and methods for systemic inhibition of cartilage degradation | |
| US7067144B2 (en) | Compositions and methods for systemic inhibition of cartilage degradation | |
| Luhmann et al. | Bone targeting for the treatment of osteoporosis | |
| Storgard et al. | Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist | |
| ES2308985T3 (es) | Disoluciones y procedimientos para la inhibicion del dolor, inflamacion y degradacion del cartilago. | |
| AU2003212898A1 (en) | Compositions and methods for systemic inhibition of cartilage degradation | |
| Roy et al. | Molecular targets in arthritis and recent trends in nanotherapy | |
| US11771744B2 (en) | Compositions and methods for inhibiting the biological activity of soluble biomolecules | |
| US9260707B2 (en) | Compounds for inhibition of MMP13-substrate interactions and methods of use thereof to treat osteoarthritis and cartilage degeneration | |
| Kou et al. | Matrix metalloproteinase inspired therapeutic strategies for bone diseases | |
| WO2019089506A1 (en) | Heterotopic ossification and method of treatment | |
| US11793857B2 (en) | Hard tissue therapeutics | |
| Homandberg et al. | Extracellular matrix fragments as regulators of cartilage metabolism in health and disease | |
| Fazal-Ur-Rehman et al. | Kartogenin induced chondrogenesis of stem cells and cartilage repair | |
| Homandberg et al. | The Role of Extracellular Matrix Fragments in the Autocrine Regulation of Cartilage Metabolism |